Targeting Aurora Kinase B Attenuates Chemoresistance in Glioblastoma via a Synergistic Manner with Temozolomide

ConclusionElevated AURKB expression was strongly correlated to TMZ resistant acquisition and poor prognosis, furthermore, targeting AURKB would be a potential therapeutic target for GBM patients.
Source: Pathology Research and Practice - Category: Pathology Source Type: research

Related Links:

Publication date: Available online 14 September 2019Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Alexandra A.P. Mansur, Anderson J. Caires, Sandhra M. Carvalho, Nadia S.V. Capanema, Isadora C. Carvalho, Herman S. MansurAbstractGlioblastoma (GBM) is the utmost aggressive and lethal primary brain cancer, which has a poor prognosis and remains virtually incurable. Nanomedicine with emerging disruptive nanotechnology alternatives, including designed supramolecular nanohybrids has excellent potential as multimodal tools against cancer by combining nanomaterials, biomacromolecules, and drugs. Thus, we developed and c...
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Dihydroartemisinin (DHA) has been shown to exert anticancer activity through iron-dependent reactive oxygen species (ROS) generation, which is similar to ferroptosis, a novel form of cell death. However, wheth...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
A number of circular RNAs (circRNAs) have been identified in various cancer including F-box and WD repeat domain containing 7 (FBXW7) circular RNA (circ-FBXW7), which can suppress glioma cell growth. However, ...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
Management to host conference call today at 8:30 a.m. Eastern SAN DIEGO, Sept. 12, 2019 -- (Healthcare Sales &Marketing Network) -- Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today announced that the Toca 5 P... Biopharmaceuticals, Oncology Tocagen, glioma, brain cancer, gene therapy
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Gliomas account for the majority of primary human brain tumors and remain a challenging neoplasm for cure due to limited therapeutic options. Cell adhesion molecules play pivotal roles in the growth and progre...
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
DNA methylation is an important regulator of gene expression and may provide an important basis for effective glioma diagnosis and therapy. Here, we explored specific prognosis subtypes based on DNA methylation status using 653 gliomas from The Cancer Genome Atlas (TCGA) database. Five subgroups were distinguished by consensus clustering using 11,637 cytosines preceding a guanosine (CpGs) that significantly influenced survival. The specific DNA methylation patterns were correlated with age, tumor stage, and prognosis. Additionally, weighted gene co-expression network analysis (WGCNA) analysis of CpG sites revealed that 11 ...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
Growing evidences indicate that circular RNAs (circRNAs) play an important role in the regulation of biological behavior of tumor. We aim to explore the role of circRNA in glioma and elucidate how circRNA acts.
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Research Source Type: research
LncRNA PLAC2 has been characterized as a tumor suppressive lncRNA in glioma. We investigated the role of PLAC2 in non-small cell lung cancer (NSCLC).
Source: BMC Pulmonary Medicine - Category: Respiratory Medicine Authors: Tags: Research article Source Type: research
Abstract PURPOSE: The 2-part, phase 1/2a, open-label study (NCT01677741) sought to determine the safety, tolerability, pharmacokinetics, and preliminary activity of dabrafenib in pediatric patients with advanced BRAF V600-mutated cancers. EXPERIMENTAL DESIGN: This phase 1 dose-finding part treated patients aged 1 to 52 weeks and 52% undergoing treatment at data cutoff date. The most common grade 3/4 adverse events suspected to be related to study drug were maculopapular rash and arthralgia (2 patients each). No dose-limiting toxicities were observed. Pharmacokinetic analyses showed a dose-dependent increase i...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsThe present study suggests that overexpression ofCD44 is associated with a poor prognosis for grade II/III glioma patients. Moreover, our findings suggest thatCD44 could serve as a prognostic biomarker in grade II/III glioma patients.
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain Tumor | Cancer | Cancer & Oncology | Databases & Libraries | Genetics | Glioma | Pathology | Study | Temodar